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Aims To examine associations of below-target and target dose of enalapril, an angiotensin-converting enzyme (ACE)
inhibitor, with outcomes in patients with heart failure and reduced ejection fraction (HFrEF) in the Studies of Left
Ventricular Dysfunction (SOLVD) Treatment trial.
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Methods
and results
Two thousand five hundred and sixty-nine patients with HFrEF (ejection fraction ≤35%) were randomized to
below-target (5–10 mg/day) dose placebo (n = 1284) or enalapril (n = 1285). One month post-randomization,
blind up-titration to target (20 mg/day) dose was attempted for both study drugs in 2458 patients. Among the
1444 patients who achieved dose up-titration (placebo, n= 748; enalapril, n= 696; mean dose for both groups, 20.0
mg/day), target dose enalapril (vs. target dose placebo) was associated with a 9% absolute lower risk of the combined
endpoint of heart failure hospitalization or all-cause mortality [adjusted hazard ratio (HR) 0.70; 95% confidence
interval (CI) 0.60–0.81; P < 0.001] during 4 years of follow-up. Among the 1014 patients who could not achieve
target dose (placebo, n= 486; enalapril, n= 528; mean dose for both groups, 8.8 mg/day), below-target dose enalapril
(vs. below-target dose placebo) was associated with a 12% absolute lower risk of the combined endpoint of heart
failure hospitalization or all-cause mortality (adjusted HR 0.68; 95% CI 0.57–0.81; P < 0.001). Among the 1224
patients receiving enalapril, target (vs. below-target) dose had no association with the combined endpoint of heart
failure hospitalization or all-cause mortality (adjusted HR 1.04; 95% CI 0.87–1.23; P = 0.695).
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Conclusion In patients with HFrEF, the clinical benefits of ACE inhibitors appear to be similar at both below-target and target
doses.
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Introduction
Heart failure (HF) is a chronic condition and a major source of
mortality and morbidity.1–4 Angiotensin-converting enzyme (ACE)
inhibitors have been shown to reduce the risk of death and hos-
pital admission in patients with HF and reduced ejection fraction
(HFrEF). Major HF guidelines recommend initial low-dose ACE
inhibitor therapy followed by higher target doses as tolerated.5,6
This recommendation is based in part on the findings from the
Treatment arm of the double-blind Studies of Left Ventricular Dys-
function (SOLVD) trial, in which patients were randomized to
receive 2.5–20 mg daily doses of either placebo or enalapril, an
ACE inhibitor.7 Although SOLVD was designed to use study drugs
at higher target (20 mg/day) doses, the final mean daily dose of
either study drug was 11 mg and at the final visit, 49% of patients
in either treatment group were receiving target doses.7 Thus, the
beneficial effects of enalapril in SOLVD may not be attributed to
the use of higher target doses. To the best of our knowledge,
comparative associations of the two doses of enalapril used in the
SOLVD trial have never been published. The objective of the cur-
rent analysis is to examine associations of target and below-target
dose enalapril with outcomes in the SOLVD Treatment trial.
Methods
Data source and study population
The current study is based on the public-use copy of the SOLVD
Treatment trial obtained from the National Heart, Lung, and
Blood Institute (NHLBI), which also sponsored the trial. The
details of the design, methods, and results of the SOLVD trial
have been reported previously.7 Briefly, 2569 patients with HFrEF
[ejection fraction (EF) ≤35%], mostly with NYHA class II or III
symptoms, who tolerated a pre-randomization stabilization phase
with single-blinded enalapril of 5 mg/day for a week were ran-
domized to receive either placebo (n = 1284) or enalapril (n
= 1285) at an initial dose of 5–10 mg/day in a double-blind
fashion.
During the month following randomization, following a
protocol-driven up-titration process, study investigators double-blindly
up-titrated the dose of both study drugs to a target dose of 20 mg/day
if patients did not have symptomatic hypotension or worsening renal
function.7,8 The current analysis is restricted to 2458 of the 2569
patients who underwent the dose up-titration process. Overall, 61%
(748 of 1234) of patients in the placebo group and 57% (696 of 1224)
of patients in the enalapril group received the target (20 mg daily)
dose (Figure 1). Overall, 58.7% (1444 of 2458) of patients received the
target dose of the study drugs.
Study outcomes
The primary outcome for the current analysis was all-cause mortality
during 4.6 years (average, 2.7 years) of follow-up, which was also the
primary outcome in the SOLVD trial.7 Secondary outcomes included
cardiovascular and HF mortality, all-cause, cardiovascular, and HF
hospitalizations, and the combined endpoint of HF hospitalization or
all-cause mortality. All endpoints were classified by study investigators
at each centre on the basis of blinded chart reviews and interviews of
family members. ..
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.. Statistical analysis
Baseline characteristics of study participants receiving below-target
and target doses of the study drugs were compared separately within
the placebo and enalapril groups using Pearson’s 𝜒2 test and Student’s
t-test as appropriate. Because doses of both enalapril and placebo
were up-titrated double-blindly, we used two separate approaches
to examine the dose response in the SOLVD trial. First, we exam-
ined the association of enalapril with outcomes separately in the
target and below-target groups. This was done first by comparing
target dose enalapril with target dose placebo and then by com-
paring below-target dose enalapril with below-target dose placebo.
Second, we examined the association of target dose with outcomes
separately in the enalapril and the placebo groups. This was done
by comparing target dose enalapril with below-target dose enalapril
and then by comparing target dose placebo with below-target dose
placebo.
For both approaches, we used multivariable Cox proportional haz-
ard models that were adjusted for all baseline characteristics dis-
played in Table 1. We used the same models to generate adjusted
survival curves for target vs. below-target dose patients, separately
for the enalapril and the placebo groups. Because systolic blood pres-
sure and serum creatinine were the two key variables used for dose
up-titration eligibility, to examine their confounding effect on the asso-
ciation between dose and primary outcome, we performed additional
analysis adjusting for these two variables. We also compared the total
number of all-cause, cardiovascular, and HF hospitalizations, and tested
for statistical significance as appropriate using Student’s t-test or the
Wilcoxon rank sum test. All statistical tests were two-tailed with 95%
confidence intervals (CIs) and a P-value <0.05 was considered sig-
nificant. IBM SPSS Statistics for Windows, version 22.0 (IBM Corp.,
Armonk, NY, USA) was used for all data analysis.
Results
Baseline characteristics
Overall, the 2458 patients included in the current analysis had a
mean age (± standard deviation) of 60 (±10) years, a mean EF of
25 (±7)%, 20% were women, and 15% were African American.
Baseline characteristics between patients receiving below-target
and target dose of the study drugs are presented in Table 1
separately for patients in the placebo and enalapril groups. Mean
systolic blood pressure was higher and mean serum creatinine was
lower among patients receiving target dose of both placebo and
enalapril, reflecting blind dose up-titration (Table 1). Other baseline
characteristics are displayed in Table 1.
Overall, the mean dose of the study drugs for patients in the
placebo and enalapril groups was 15.6 and 15.2 mg/day, respectively
(P = 0.077). The mean dose of the study drugs for patients in
the below-target and target dose groups was 8.8 and 20.0 mg/day,
respectively, which was similar for both placebo and enalapril
groups (Table 1). All patients in the target dose group received a 20
mg/day dose. The vast majority of the patients in the below-target
group received 10 mg/day (n = 774); 76% and 77% of patients in
the placebo and enalapril groups, respectively, received this dose.
Other below-target doses were: 2.5 mg/day (n = 23), 5 mg/day (n
= 215), 7.5 mg/day (n = 1), 15 mg/day (n = 1).
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n=486
Continued at below-target  
dose of 5–10 mg/day
Mean SBP: 121 mmHg
Mean SCr: 1.3 mg/dL
All-cause mortality: 40%
n=528
Continued at below-target  
dose of 5–10 mg/day
Mean SBP: 122 mmHg
Mean SCr: 1.3 mg/dL
All-cause mortality: 35%
n=748
Up-titrated to target dose of 
20 mg/day
Mean SBP: 127 mmHg
Mean SCr: 1.2 mg/dL
All-cause mortality: 38%
n=696
Up-titrated to target dose of 
20 mg/day
Mean SBP: 128 mmHg
Mean SCr: 1.2 mg/dL
All-cause mortality: 33%
2%
5%
2%
5%
Placebo group
(n=1234) 
Enalapril group
(n=1224) 
Below-target dose 
(n=1014)
Target dose 
(n=1444)
One month post-randomization 
Figure 1 Flow chart for study cohort assembly for the current analysis. In the SOLVD Treatment trial, 2569 patients with heart failure and
left ventricular ejection fraction ≤35% were randomized to below-target (5–10mg/day) dose enalapril or matching placebo at baseline. One
month post-randomization, double-blind up-titration to target (20mg/day) dose was attempted per protocol for both study drugs in 2458
patients, based primarily on systolic blood pressure (SBP) and serum creatinine (SCr). Dose up-titration was achieved in 1444 patients and
1014 patients continued on below-target dose. Baseline SBP and SCr and all-cause mortality during 4.6 (average, 2.7) years of follow-up for
each group are displayed in their respective cells.
Enalapril and all-cause mortality in the
original SOLVD cohort
As previously reported, among the 2569 patients enrolled in the
SOLVD trial, the primary endpoint of all-cause mortality occurred
in 40% and 35% of patients in the placebo and the enalapril groups,
respectively [hazard ratio (HR) when enalapril was compared with
placebo, 0.84; 95% CI 0.74–0.96; P = 0.008).7
Enalapril and all-cause mortality in the
dose up-titration cohort
Among the 2458 patients included in the current analysis, all-cause
mortality occurred in 39% and 34% of patients receiving placebo
and enalapril, respectively (HR associated with enalapril use, 0.83;
95% CI 0.73–0.95; P = 0.005).
Enalapril and outcomes within the target
dose group
Among patients in the target dose group (n = 1444), all-cause
mortality occurred in 38% and 33% of patients receiving target dose
placebo and target dose enalapril, respectively (HR associated with
target dose enalapril, 0.91; 95%CI 0.83–0.99; P= 0.029; Table 2 and
Figure 2). This association remained unchanged after multivariable ..
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. risk adjustment (adjusted HR 0.90; 95% CI 0.82–0.98; P = 0.017;
Table 2). Target dose enalapril was also associated with a lower
risk of HF hospitalization (adjusted HR 0.75; 95% CI 0.68–0.83;
P< 0.001), and consequently a lower risk of the combined endpoint
of HF hospitalization or all-cause mortality (adjusted HR 0.70;
95% CI 0.60–0.81; P < 0.001; Table 2). Associations of target
dose enalapril (vs. target dose placebo) with other outcomes are
displayed in Table 2.
Enalapril and outcomes within
the below-target dose group
Among patients in the relatively smaller below-target dose group
(n = 1014), all-cause mortality occurred in 40% and 35% of
patients receiving below-target dose placebo and below-target
dose enalapril, respectively (HR associated with below-target
dose enalapril, 0.91; 95% CI 0.82–1.01; P = 0.068; Table 2 and
Figure 2). This association remained unchanged after multivariable
risk adjustment (adjusted HR 0.90; 95% CI 0.81–1.00; P = 0.057;
Table 2). Below-target dose enalapril was also associated with
a lower risk of HF hospitalization (adjusted HR 0.79; 95% CI
0.71–0.89; P < 0.001) as well as the combined endpoint of HF
hospitalization or all-cause mortality (HR 0.68; 95% CI 0.57–0.81;
P < 0.001; Table 2). Associations of below-target dose enalapril (vs.
below-target dose placebo) with other outcomes are displayed in
Table 2.
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Table 1 Baseline characteristics of patients receiving below-target doses vs. target doses of the study drugs in the
SOLVD Treatment trial, for the placebo and enalapril groups separately
Placebo (n = 1234) Enalapril (n = 1224)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Below-target dose
(n = 486)
Target dose
(n = 748)
P-value Below-target dose
(n = 528)
Target dose
(n = 696)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 61 (±10) 60 (±9) 0.061 60 (±11) 60 (±10) 0.662
Female* 128 (26) 119 (16) <0.001 102 (19) 127 (18) 0.634
African American 91 (19) 86 (12) <0.001 95 (18) 100 (14) 0.086
Dose of study drugs (mg/day) 8.8 (±2.3) 20.0 (±0.0) <0.001 8.8 (±2.2) 20.0 (±0.0) <0.001
Current smoker* 87 (18) 178 (24) 0.014 127 (24) 155 (22) 0.463
New York Heart Association class
I 60 (12) 113 (15) <0.001 63 (12) 110 (16) 0.083
II 252 (52) 428 (57) 275 (52) 374 (54)
III 152 (31) 200 (27) 181 (34) 205 (30)
IV 22 (5) 7 (1) 9 (2) 7 (1)
Past medical history
Chronic heart failure aetiology
Ischaemic causes 337 (69) 556 (74) 0.118 384 (73) 479 (69) 0.095
Other causes 54 (11) 62 (8) 59 (11) 71 (10)
Unknown causes 95 (20) 130 (17) 85 (16) 146 (21)
Acute myocardial infarction 310 (64) 492 (66) 0.474 362 (69) 451 (65) 0.168
Hypertension 203 (42) 307 (41) 0.800 204 (39) 314 (45) 0.023
Diabetes mellitus* 135 (28) 195 (26) 0.508 118 (22) 177 (25) 0.212
Angina pectoris 188 (39) 295 (39) 0.791 199 (38) 247 (36) 0.428
Atrial fibrillation† 36 (7) 46 (6) 0.386 46 (9) 62 (9) 0.905
Cardiothoracic ratio >0.5 284 (58) 410 (55) 0.210 307 (58) 402 (58) 0.892
Clinical findings
Pulse (beats/min) 81 (±14) 79 (±13) 0.018 80 (±14) 80 (±13) 0.579
Systolic blood pressure (mmHg) 121 (±18) 127 (±16) <0.001 122 (±18) 128 (±17) <0.001
Diastolic blood pressure (mmHg) 75 (±10) 77 (±10) <0.001 76 (±10) 78 (±10) <0.001
Weight (kg) 76 (±10) 77 (±9) 0.003 76 (±9) 77 (±8) 0.049
Laboratory data
Serum sodium (mEq/L) 140 (±3) 140 (±3) 0.413 140 (±3) 140 (±3) 0.195
Serum potassium (mEq/L) 4.3 (±0.47) 4.3 (±0.45) 0.688 4.2 (±0.44) 4.3 (±0.46) 0.334
Serum creatinine (mEq/L) 1.3 (±0.32) 1.2 (±0.29) 0.002 1.3 (±0.32) 1.2 (±0.29) 0.033
Ejection fraction (%) 25 (±7) 25 (±7) 0.608 25 (±7) 25 (±7) 0.714
Medications
Beta-blockers 26 (5) 62 (8) 0.050 41 (8) 59 (9) 0.652
Digitalis† 305 (63) 541 (72) <0.001 339 (64) 464 (67) 0.369
Diuretics 3399 (82) 650 (87) 0.021 444 (84) 598 (86) 0.373
Potassium-sparing diuretics 39 (8) 76 (10) 0.207 46 (9) 68 (10) 0.528
Calcium channel blockers* 158 (33) 243 (33) 0.993 141 (27) 223 (32) 0.043
Nitrates† 226 (47) 312 (42) 0.097 228 (43) 255 (37) 0.020
Anti-arrhythmics 111 (23) 145 (19) 0.144 116 (22) 160 (23) 0.673
Potassium supplements 233 (48) 369 (49) 0.633 262 (50) 360 (52) 0.466
Anti-coagulants 93 (19) 110 (15) 0.040 87 (17) 106 (15) 0.553
Anti-platelets 189 (39) 230 (31) 0.003 203 (38) 203 (29) 0.001
Values are mean (±SD) or numbers and proportion of patients (%).
*P-value <0.05, when patients in the below-target dose enalapril group were compared with those in the below-target dose placebo group.
†P-value <0.05, when patients in the target dose enalapril group were compared with those in the target dose placebo group.
Target dose and outcomes within
the enalapril group
Among patients in the enalapril group (n = 1224), all-cause mor-
tality occurred in 35% and 33% of patients receiving below-target ..
..
..
..
..
..
.. dose enalapril and target dose enalapril, respectively (HR associ-
ated with target dose enalapril, 0.89; 95% CI 0.74–1.09; P = 0.26,
Table 3). Multivariable-adjusted HR for this association was 1.01
(95% CI 0.82–1.24; P = 0.95; Table 3 and Figure 3). HR adjusted
for baseline systolic blood pressure and serum creatinine, the
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Table 2 Outcomes by randomization to placebo vs. enalapril in the SOLVD Treatment trial, separately in the target
and below-target dose groups
Target dose (n = 1444)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Events (%) Hazard ratio (95% CI); P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Placebo
(n = 748)
Enalapril
(n = 696)
ARDa Unadjusted Age, sex, race
adjusted
Multivariable
adjustedb
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
All-cause 287 (38%) 233 (33%) –5% 0.91 (0.83–0.99);
P = 0.029
0.91 (0.83–0.99);
P = 0.033
0.90 (0.82–0.98);
P = 0.017
Cardiovascular 257 (34%) 207 (30%) –4% 0.91 (0.83–0.99);
P = 0.032
0.91 (0.83–0.99);
P = 0.034
0.90 (0.81–0.98);
P = 0.020
Heart failure 97 (13%) 82 (12%) –1% 0.92 (0.80–1.07);
P = 0.286
0.93 (0.80–1.07);
P = 0.296
0.91 (0.78–1.06);
P = 0.236
Hospitalization
All-cause 556 (74%) 474 (68%) –6% 0.88 (0.83–0.93);
P < 0.001
0.88 (0.83–0.93);
P < 0.001
0.87 (0.82–0.93);
P < 0.001
Cardiovascular 470 (63%) 386 (56%) –7% 0.88 (0.82–0.94);
P < 0.001
0.88 (0.82–0.94);
P < 0.001
0.87 (0.81–0.93);
P < 0.001
Heart failure 270 (36%) 172 (25%) –11% 0.78 (0.71–0.86);
P < 0.001
0.77 (0.70–0.85);
P < 0.001
0.75 (0.68–0.83);
P < 0.001
Combined endpoint of heart failure
hospitalization or all-cause mortality
415 (55%) 322 (46%) –9% 0.74 (0.64–0.85);
P < 0.001
0.73 (0.63–0.85);
P < 0.001
0.70 (0.60–0.81);
P < 0.001
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Below-target dose (n = 1014)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Events (%) Hazard ratio (95% CI); P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Placebo
(n = 486)
Enalapril
(n = 528)
ARDa Unadjusted Age, sex, race
adjusted
Multivariable
adjustedb
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
All-cause 196 (40%) 185 (35%) –5% 0.91 (0.82–1.01);
P = 0.068
0.92 (0.83–1.01);
P = 0.091
0.90 (0.81–1.00);
P = 0.057
Cardiovascular 178 (37%) 163 (31%) –6% 0.90 (0.81–1.00);
P = 0.047
0.90 (0.81–1.01);
P = 0.064
0.89 (0.80–0.99);
P = 0.039
Heart failure 66 (14%) 59 (11%) –3% 0.89 (0.75–1.06);
P = 0.183
0.91 (0.76–1.09);
P = 0.301
0.91 (0.75–1.10);
P = 0.310
Hospitalization
All-cause 365 (75%) 375 (71%) –4% 0.92 (0.86–0.99);
P = 0.022
0.92 (0.86–0.99);
P = 0.024
0.93 (0.86–1.00);
P = 0.054
Cardiovascular 308 (63%) 302 (57%) –6% 0.90 (0.83–0.98);
P = 0.011
0.90 (0.83–0.97);
P = 0.009
0.89 (0.82–0.97);
P = 0.008
Heart failure 181 (37%) 140 (27%) –10% 0.79 (0.71–0.89);
P < 0.001
0.80 (0.72–0.90);
P < 0.001
0.79 (0.71–0.89);
P < 0.001
Combined endpoint of heart failure
hospitalization or all-cause mortality
285 (59%) 249 (47%) –12% 0.71 (0.60–0.84);
P < 0.001
0.71 (0.60–0.85);
P < 0.001
0.68 (0.57–0.81);
P < 0.001
ARD, absolute risk difference; CI, confidence interval.
aEstimated by subtracting event rates in the enalapril group from those in the placebo group.
bAdjusted for all variables included in Table 1.
two characteristics that were used to determine blind up-titration
suitability, was 0.97 (95% CI 0.80–1.18; P = 0.76). Target dose
enalapril was not associated with the combined endpoint of HF
hospitalization or all-cause mortality (HR 1.04; 95% CI 0.87–1.23;
P = 0.70; Table 3). Associations of target dose enalapril (vs.
below-target dose enalapril) with other outcomes are displayed
in Table 3. ..
..
..
..
..
..
..
..
..
.. Target dose and outcomes within
the placebo group
Among patients in the placebo group (n= 1234), all-cause mortality
occurred in 40% and 38% of patients receiving below-target dose
placebo and target dose placebo, respectively (HR associated with
target dose placebo, 0.91; 95% CI 0.76–1.09; P = 0.28; Table 3).
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Follow-up (years)
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y
Enalapril
Placebo
Within target dose group 
(n=1444)
HR 0.91 (95% CI 0.83–0.99); P=0.029
Number at risk
Placebo 748 638 555 364 106
Enalapril 696 622 560 359 130
Follow-up (years)
Number at risk
Placebo 486 414 348 203 66
Enalapril 528 463 403 237 59
A
ll-
ca
u
se
 m
o
rt
al
it
y
Within below-target dose group 
(n=1014)
Enalapril
HR 0.91 (95% CI 0.82–1.01); P=0.068
Placebo
Figure 2 Kaplan–Meier plots for all-cause mortality in patients with heart failure and left ventricular ejection fraction ≤35% in the SOLVD
Treatment trial, by randomization to enalapril or placebo, separately within the below-target and target dose groups. HR, hazard ratio; CI,
confidence interval.
Multivariable-adjusted HR for this association was 0.96 (95% CI
0.79–1.16; P = 0.67; Table 3 and Figure 3). As observed in the
enalapril group, HR adjusted for baseline systolic blood pressure
and serum creatinine was similar to that observed after multivari-
able adjustment (HR 0.98; 95% CI 0.81–1.18; P = 0.79). Associa-
tions of target dose placebo (vs. below-target dose placebo) with
other outcomes are displayed in Table 3.
Associations with total number
of hospitalizations
Among the 2458 patients included in the current analysis, patients
in the enalapril group had 32% fewer HF hospitalizations (634 vs.
931 in the placebo group; P < 0.001; Table 4). There was no
difference in total number of hospitalizations between the two dose
groups receiving enalapril or placebo (Table 4).
Target dose and outcomes in SOLVD,
ATLAS, NETWORK, and HEAAL
The design, name and dose of study drugs, demographics, and
key outcomes data of the current study and the randomized con-
trolled trials (RCTs) of higher (vs. lower) doses of ACE inhibitors
or angiotensin II receptor blockers (ARBs) are presented in Table 5.
In none of these RCTs did high dose reduce the risk of death ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
. (Table 5).9–11 The composite endpoint of mortality or HF hospi-
talization was significantly reduced in two of these trials and both
were driven by a reduction in the risk of HF hospitalization.9,11
The point estimate for risk reduction for HF hospitalization in
the ATLAS trial was not provided,9 and in the HEAAL trial there
was a significant but modest 1% reduction in HF hospitalization
per 100 patient-years of follow-up in the high-dose losartan
group.11
Discussion
Findings from this post hoc analysis of the SOLVD data demon-
strate that enalapril (vs. placebo) use was associated with a sim-
ilar lower risk of mortality separately in the below-target and
target dose groups, and that the magnitude of the absolute risk
reduction in these two dose groups was similar to that observed
in the main trial.7 When we examined the association of target
(vs. below-target) dose with mortality, we found similar mod-
est non-significant unadjusted associations in both placebo and
enalapril groups reflecting selection bias and blind up-titration
of the study drugs. This lack of evidence of greater mortality
benefit from higher target dose observed in our study is generally
consistent with findings from previous RCTs comparing target (vs.
below-target) dose of ACE inhibitors or ARBs.9–11 The lower
risk of combined endpoints observed in some of these trials was
driven primarily by a modest reduction in HF hospitalization. Taken
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Table 3 Outcomes by below-target vs. target doses of the study drugs in the SOLVD Treatment trial, separately in
the enalapril and placebo groups
Enalapril (n = 1224)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Events (%) Hazard ratio (95% CI); P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Below-target
dose (n = 528)
Target dose
(n = 696)
ARDa Unadjusted Age, sex, race
adjusted
Multivariable
adjustedb
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
All-cause 185 (35%) 233 (33%) –2% 0.89 (0.74–1.09);
P = 0.257
0.91 (0.75–1.10);
P = 0.325
1.01 (0.82–1.24);
P = 0.947
Cardiovascular 163 (31%) 207 (30%) –1% 0.90 (0.74–1.11);
P = 0.326
0.92 (0.75–1.13);
P = 0.403
1.02 (0.83–1.27);
P = 0.827
Heart failure 59 (11%) 82 (12%) +1% 0.97 (0.69–1.35);
P = 0.838
0.98 (0.70–1.37);
P = 0.916
1.22 (0.85–1.74);
P = 0.286
Hospitalization
All-cause 375 (71%) 474 (68%) –3% 0.87 (0.76–0.99);
P = 0.037
0.87 (0.76–1.00);
P = 0.048
0.91 (0.78–1.05);
P = 0.173
Cardiovascular 302 (57%) 386 (56%) –1% 0.90 (0.78–1.05);
P = 0.175
0.90 (0.78–1.05);
P = 0.191
0.94 (0.81–1.11);
P = 0.478
Heart failure 140 (27%) 172 (25%) –2% 0.88 (0.70–1.10);
P = 0.264
0.90 (0.72–1.12);
P = 0.348
0.99 (0.78–1.25);
P = 0.899
Combined endpoint of heart failure
hospitalization or all-cause mortality
249 (47%) 322 (46%) –1% 0.92 (0.78–1.09);
P = 0.346
0.94 (0.80–1.11);
P = 0.485
1.04 (0.87–1.23);
P = 0.695
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Placebo (n = 1234)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Events (%) Hazard ratio (95% CI); P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Below-target
dose (n = 486)
Target dose
(n = 748)
ARDa Unadjusted Age, sex, race
adjusted
Multivariable
adjustedb
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mortality
All-cause 196 (40%) 287 (38%) –2% 0.91 (0.76–1.09);
P = 0.284
0.92 (0.76–1.10);
P = 0.349
0.96 (0.79–1.16);
P = 0.666
Cardiovascular 178 (37%) 257 (34%) –3% 0.89 (0.74–1.08);
P = 0.250
0.91 (0.75–1.11);
P = 0.347
0.94 (0.77–1.16);
P = 0.579
Heart failure 66 (14%) 97 (13%) –1% 0.91 (0.66–1.24);
P = 0.530
0.95 (0.69–1.30);
P = 0.732
1.17 (0.82–1.66);
P = 0.381
Hospitalization
All-cause 365 (75%) 556 (74%) –1% 0.95 (0.83–1.08);
P = 0.425
0.95 (0.83–1.09);
P = 0.447
1.00 (0.86–1.15);
P = 0.947
Cardiovascular 308 (63%) 470 (63%) 0% 0.95 (0.82–1.10);
P = 0.481
0.94 (0.81–1.09);
P = 0.399
0.99 (0.84–1.15);
P = 0.845
Heart failure 181 (37%) 270 (36%) –1% 0.92 (0.76–1.11);
P = 0.357
0.93 (0.77–1.13);
P = 0.454
1.03 (0.84–1.26);
P = 0.772
Combined endpoint of heart failure
hospitalization or all-cause mortality
285 (59%) 415 (56%) –3% 0.89 (0.77–1.04);
P = 0.129
0.89 (0.77–1.04);
P = 0.143
0.93 (0.79–1.09);
P = 0.374
ARD, absolute risk difference; CI, confidence interval.
aEstimated by subtracting event rates in the below-target group from those in the target group.
bAdjusted for all variables included in Table 1.
together, these findings suggest that target dose ACE inhibitor
is not associated with incremental mortality benefit beyond that
achieved at below-target dose and that other clinical benefits of
target dose, if present, are modest.
By protocol, the blind up-titration of enalapril and placebo in
the SOLVD trial was based on patients’ conditions, specifically ..
..
..
..
..
..
..
..
.. the absence of symptomatic hypotension and/or impaired kidney
function—a process that may have selected patients with a better
prognosis in the target dose group. As a result, patients receiving
both target dose enalapril and target dose placebo had significantly
higher mean systolic blood pressure and lower mean serum cre-
atinine levels at baseline (Table 1), characteristics that have been
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Figure 3 Adjusted survival plots for all-cause mortality in patients with heart failure and left ventricular ejection fraction ≤35% in the SOLVD
Treatment trial, by receipt of the below-target vs. the target dose of the study drugs, separately within the enalapril and the placebo groups.
Multivariable-adjusted Cox regression model was adjusted for all variables included in Table 1. CI, confidence interval; HR, hazard ratio.
Table 4 Total numbers of hospitalizations for any reason, cardiovascular reason, and heart failure in the SOLVD
Treatment trial, by below-target vs. target doses of the study drugs, separately in the enalapril and placebo groups
Hospitalizations for any reason,
total (mean/patient)
Hospitalizations for CV reason,
total (mean/patient)
Hospitalization for HF,
total (mean/patient)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2268 (1.9)a 1562 (1.3)b 634 (0.5)c
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Enalapril
(n = 1224)
Below-target dose
(n = 528)
Target dose
(n = 696)
Below-target dose
(n = 528)
Target dose
(n = 696)
Below-target dose
(n = 528)
Target dose
(n = 696)
1004 (1.9)d 1264 (1.8)e 679 (1.3)f 883 (1.3)g 281 (0.5)h 353 (0.5)i
P = 0.465j P = 0.612j P = 0.445j
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hospitalizations for any reason,
total (mean/patient)
Hospitalizations for CV reason,
total (mean/patient)
Hospitalization for HF,
total (mean/patient)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2738 (2.2)a 1967 (1.6)b 931 (0.8)c
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Placebo
(n = 1234)
Below-target dose
(n = 486)
Target dose
(n = 748)
Below-target dose
(n = 486)
Target dose
(n = 748)
Below-target dose
(n = 486)
Target dose
(n = 748)
1110 (2.3)d 1628 (2.2)e 800 (1.7)f 1167 (1.6)g 398 (0.8)h 533 (0.7)i
P = 0.971j P = 0.672j P = 0.682j
CV, cardiovascular; HF, heart failure.
a ,b,cP-values comparing hospitalization for any reason, cardiovascular reason, and heart failure, between placebo and enalapril, overall were derived from Student’s t-tests and
were <0.001 for all three outcomes.
d–iP-values comparing hospitalization for any reason, cardiovascular reason, and heart failure, between placebo and enalapril, separately within below-target (d0.021, f0.008,
and h0.003) and target (e0.005, g0.005, and i0.002) dose groups.
jP-values comparing hospitalization for any reason, cardiovascular reason, and heart failure, between below-target and target dose groups, were derived from the Wilcoxon
rank sum (or Mann–Whitney) tests.
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shown to be associated with better outcomes in patients with
HF.12,13 A 2% non-significant absolute reduction in unadjusted mor-
tality in the target dose enalapril (vs. below-target enalapril) group
suggests that the risk reduction associated with the higher target
dose was at best modest. However, two observations point to
another explanation—a potential selection bias. First, the modest
association of target dose and mortality disappeared when adjusted
for just systolic blood pressure and serum creatinine, and second,
similar unadjusted and adjusted associations of target dose and
mortality were also observed in the placebo group.
In the SOLVD Treatment trial, enalapril had a strong and sig-
nificant effect on HF hospitalization.7 We observed that enalapril
(vs. placebo) in both target and below-target dose use was asso-
ciated with a similar lower risk of HF hospitalization, suggesting
that a higher target dose did not provide any incremental bene-
fit for this outcome. The lack of dose effect was also supported
by our observation that neither target dose of enalapril nor target
dose of placebo had any association with HF hospitalization when
compared with their below-target dose counterparts (Table 3).
However, as explained below, these findings in terms of HF hos-
pitalization are not entirely consistent with findings from some of
the RCTs on dosing.9,11
As mentioned before, none of the three RCTs that examined
the effect of high (vs. low) doses of ACE inhibitors or ARBs
found any mortality benefit.9–11 Two of these RCTs reported a
reduction of mortality or HF hospitalization,9,11 which was driven
by a modest reduction in the risk of HF hospitalization. However,
neither had a placebo group to demonstrate the effect of low
dose compared with placebo. Findings from our study suggest that
enalapril use at both below-target and target dose of enalapril
was associated with a similar lower risk for HF hospitalizations
(Table 3). These findings are also consistent with findings from a
recent study that observed similar efficacy of sacubitril/valsartan
(vs. enalapril) in the below-target dose group (HR 0.80, 95% CI
0.70–0.93, P< 0.001) and the target dose group (HR 0.79, 95% CI
0.71–0.88, P< 0.001).14
Findings from our study have important clinical implications.
The use of higher target doses of ACE inhibitors and ARBs is
associated with a modest increase in the risk of adverse effects,
including hypotension, dizziness, hyperkalaemia, and elevation of
serum creatinine.9,15,16 The use of a higher dose of these drugs
may also preclude the initiation or up-titration of beta-blockers
and aldosterone antagonists, and switching to an angiotensin
receptor–neprilysin inhibitor (ARNI).6,17 Recent updates in HF
guidelines recommend the use of an ARNI, a combination of valsar-
tan and sacubitril, to replace ACE inhibitors in ambulatory patients
with mild to moderate chronic HFrEF who tolerate a high target
dose of ACE inhibitors.6,17
The SOLVD trial was conducted during an earlier era of HF man-
agement, which may limit generalization to contemporary HFrEF
patients. However, the SOLVD trial remains the cornerstone of the
evidence base for the use of ACE inhibitors in patients with HFrEF.
Importantly, the use of target dose ACE inhibitors in the SOLVD
trial is often cited as a rationale to recommend higher target doses
of ACE inhibitors, although data on outcomes in patients receiving
below-target and target dose have not been previously published. ..
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.. Thus, the current analysis based on the SOLVD trial is relevant
in clarifying current interpretations of the findings from that trial.
Because dose in our study was not determined by randomization,
confounding due to selection bias is possible. However, this is not
a concern as we did not observe any clinical benefit in patients
receiving higher target doses who may have had a lower risk due
to selection bias. Finally, the similar associations of below-target
and target dose enalapril with mortality observed in our study is
consistent with the similar effect of below-target and target dose
ACE inhibitors or ARBs on mortality observed in the ATLAS, NET-
WORK, and HEAAL trials.9–11
In conclusion, in patients with HFrEF enrolled in the SOLVD
trial, the use of target dose enalapril (vs. target dose placebo) and
below-target dose enalapril (vs. below-target dose placebo) was
associated with a similar lower risk of death, HF hospitalization,
or the combined endpoint of HF hospitalization or death. We also
observed that the use of target dose enalapril (vs. below-target
dose enalapril) was not associated with these outcomes or total
number of hospitalizations. Taken together with the findings from
the ATLAS, NETWORK, and HEAAL trials, these findings suggest
that ACE inhibitor use is associated with clinical benefits for those
who can tolerate a higher dose as well as for those who cannot
tolerate a higher dose or may not be eligible for such a dose, and
that incremental clinical benefits associated with a higher dose, if
present, are modest.
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